<DOC>
<DOCNO>EP-0618900</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2518	A61K3147	C07D21500	A61P2530	C07D21700	C07D40508	A61K314725	A61K31472	C07D21720	A61K31472	C07D40500	A61P2500	C07D21506	A61P2500	C07D21704	A61K3147	C07D21502	C07D21718	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	C07D	A61P	C07D	C07D	A61K	A61K	C07D	A61K	C07D	A61P	C07D	A61P	C07D	A61K	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61K31	C07D215	A61P25	C07D217	C07D405	A61K31	A61K31	C07D217	A61K31	C07D405	A61P25	C07D215	A61P25	C07D217	A61K31	C07D215	C07D217	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Tetrahydroisoquinoline compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R1 is optionally alkylated carbamoyl; R2 represents an aliphatic group optionally substituted by hydroxy or alkoxy; E represents an alkylene chain optionally substitued by one or more alkyl groups; and G represents phenyl or phenyl substituted by one or more of alkyl, alkoxy, halo, hydroxy, polyhaloalkyl, polyhaloalkoxy, cyano, alkylthio, alkylsulphinyl, alkylsulphonyl, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), optionally alkylated carbamoyl, or G represents a phenyl ring having fused thereto a heterocyclic or aromatic carbocyclic ring; and O 
&
cir
&
 _-acylated derivatives thereof which provide lipophilic esters have utility in analgesia and in the treatment of psychoses (e.g. schizophrenia), Parkinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
KNOLL AG
</APPLICANT-NAME>
<APPLICANT-NAME>
KNOLL AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KOZLIK ANTONIN
</INVENTOR-NAME>
<INVENTOR-NAME>
NEEDHAM PATRICIA LESLEY
</INVENTOR-NAME>
<INVENTOR-NAME>
SARGENT BRUCE JEREMY
</INVENTOR-NAME>
<INVENTOR-NAME>
KOZLIK, ANTONIN
</INVENTOR-NAME>
<INVENTOR-NAME>
NEEDHAM, PATRICIA, LESLEY
</INVENTOR-NAME>
<INVENTOR-NAME>
SARGENT, BRUCE, JEREMY
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to novel tetrahydroisoquinoline 
compounds, to pharmaceutical compositions 
containing the compounds, methods of preparing the 
compounds and the use of the compounds in analgesia and 
in the treatment of psychoses (for example 
schizophrenia), Parkinsons's disease, Lesch-Nyan 
syndrome, attention deficit disorder or cognitive 
impairment or in the relief of drug dependence or 
tardive dyskinesia. The present invention provides tetrahydroisoquinoline 
compounds of formula I 
 
and pharmaceutically acceptable salts thereof, in 
which:- 
R1 represents one or more substituents selected from H, 
halo, hydroxy, alkyl of 1 to 3 carbon atoms (optionally 
substituted by hydroxy), alkoxy of 1 to 3 carbon atoms, 
alkylthio of 1 to 3 carbon atoms, alkylsulphinyl of 1 to 
3 carbon atoms, alkylsulphonyl of 1 to 3 carbon atoms, 
nitro, cyano, polyhaloalkyl of 1 to 3 carbon atoms, 
polyhaloalkoxy of 1 to 3 carbon atoms, phenyl 
(optionally substituted by one or more substituents 
selected from halo, alkyl of 1 to 3 carbon atoms or 
alkoxy of 1 to 3 carbon atoms), or R1 is carbamoyl 
optionally alkylated by one or two alkyl groups each 
independently of 1 to 3 carbon atoms;  
 R2 represents an aliphatic group containing 1 to 3 
carbon atoms optionally substituted by hydroxy or alkoxy 
containing 1 to 3 carbon atoms; E represents an alkylene chain containing 2 to 5 carbon 
atoms optionally substituted by one or more alkyl groups 
containing 1 to 3 carbon atoms, and G represents phenyl or phenyl substituted by one or 
more substituents which may be the same or different, 
and which are independently alkyl of 1 to 3 carbon 
atoms, alkoxy of 1 to 3 carbon atoms, halo, hydroxy, 
polyhaloalkyl of 1 to 3 carbon atoms, polyhaloalkoxy of 
1 to 3 carbon atoms, cyano, alkylthio of 1 to 3 carbon 
atoms, alkylsulphinyl of 1 to 3 carbon atoms, 
alkylsulphonyl of 1 to 3 carbon atoms, phenyl 
(optionally substituted by one or more substituents 
selected from halo, alkyl of 1 to 3 carbon atoms or 
alkoxy of 1 to 3 carbon atoms), carbamoyl optionally 
alkylated by one or two alkyl groups each independently 
of 1 to 3 carbon atoms, or G represents a phenyl ring 
having fused thereto a heterocyclic or aromatic 
carbocyclic ring; and O-acylated derivatives thereof. In preferred compounds of formula I, the hydroxy 
group is in the 7-position. Accordingly one group of 
preferred compounds of the invention is represented by 
formula II  
 
 
and pharmaceutically acceptable salts thereof, in which 
R1, R2, E and G
</DESCRIPTION>
<CLAIMS>
Tetrahydroisoquinoline compounds of formula I 

 
and pharmaceutically acceptable salts thereof, in 

which:- 

R
1
 represents one or more substituents selected from H, 
halo, hydroxy, alkyl of 1 to 3 carbon atoms (optionally 

substituted by hydroxy), alkoxy of 1 to 3 carbon atoms, 
alkylthio of 1 to 3 carbon atoms, alkylsulphinyl of 1 to 

3 carbon atoms, alkylsulphonyl of 1 to 3 carbon atoms, 
nitro, cyano, polyhaloalkyl of 1 to 3 carbon atoms, 

polyhaloalkoxy of 1 to 3 carbon atoms, phenyl 
(optionally substituted by one or more substituents 

selected from halo, alkyl of 1 to 3 carbon atoms or 
alkoxy of 1 to 3 carbon atoms), or R
1
 is carbamoyl 
optionally alkylated by one or two alkyl groups each 

independently of 1 to 3 carbon atoms; 
R
2
 represents an aliphatic group containing 1 to 3 
carbon atoms optionally substituted by hydroxy or alkoxy 

containing 1 to 3 carbon atoms; 
E represents an alkylene chain containing 2 to 5 carbon 
atoms optionally substituted by one or more alkyl groups 

containing 1 to 3 carbon atoms, 
and G represents phenyl or phenyl substituted by one or 
more substituents which may be the same or different,  

 
and which are independently alkyl of 1 to 3 carbon 
atoms, alkoxy of 1 to 3 carbon atoms, halo, hydroxy, 

polyhaloalkyl of 1 to 3 carbon atoms, polyhaloalkoxy of 
1 to 3 carbon atoms, cyano, alkylthio of 1 to 3 carbon 

atoms, alkylsulphinyl of 1 to 3 carbon atoms, 
alkylsulphonyl of 1 to 3 carbon atoms, phenyl 

(optionally substituted by one or more substituents 
selected from halo, alkyl of 1 to 3 carbon atoms or 

alkoxy of 1 to 3 carbon atoms), carbamoyl optionally 
alkylated by one or two alkyl groups each independently 

of 1 to 3 carbon atoms, or G represents a phenyl ring 
having fused thereto a heterocyclic or aromatic 

carbocyclic ring; 
and compounds of formula I which are 
O
-acylated in the 
5,6,7 or 8-position in the tetrahydroisoquinoline ring 

as represented by compounds of formula III 

 
in which R
7
 represents an acyl group derived from a 
carboxylic acid having 6 to 20 carbon atoms. 
Compounds of formula I as claimed in claim 1 wherein 
R
1
 represents H, halo, hydroxy, alkyl of 1 to 3 carbon 
atoms, alkoxy of 1 to 3 carbon atoms, alkylthio of 1 to 

3 carbon atoms, nitro, polyfluoroalkyl of 1 to 3 carbon 
atoms, polyfluoroalkoxy of 1 to 3 carbon atoms or phenyl 

optionally substituted by fluoro, chloro, bromo, methyl 
or methoxy.  

 
Compounds of formula I as claimed in any preceding 
claim wherein R
1
 represents H, fluoro, chloro, bromo, 
hydroxy, methyl, methoxy, phenyl or nitro. 
Compounds of formula I as claimed in any preceding 
claim wherein R
2
 represents an alkyl group containing 1 
to 3 carbon atoms optionally substituted by hydroxy or 

by methoxy or R
2
 represents an alkenyl group of 2 or 3 
carbon atoms. 
Compounds of formula I as claimed in claim 4 wherein 
R
2
 represents methyl, ethyl, 2-hydroxyethyl or 2-methoxyethyl 
or R
2
 represents allyl. 
Compounds of formula I as claimed in any preceding 
claim wherein the group E represents -(CH
2
)
2
-, -(CH
2
)
3
-, 
-(CH
2
)
4
-, -(CH
2
)
5
- or -CH
2
CMe
2
CH
2
-. 
Compounds of formula I as claimed in any preceding 
claim wherein G represents phenyl or phenyl substituted 

by one or more substituents which are independently 
alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon 

atoms, halo, hydroxy, polyfluoroalkyl of 1 to 3 carbon 
atoms, polyfluoroalkoxy of 1 to 3 carbon atoms or phenyl 

optionally substituted by fluoro, chloro, bromo, methyl 
or methoxy or G represents naphthyl or dihydrobenzofuran-7-yl. 
Compounds of formula I as claimed in any preceding 
claim wherein G represents phenyl or phenyl substituted 

by methyl, hydroxy, methoxy, methylthio, fluoro, chloro, 
bromo, trifluoromethyl, cyano or trifluoromethoxy or G 

represents a naphthyl or dihydrobenzo[b]furan-7-yl 

group. 
Compounds of formula I as claimed in any preceding 
claim wherein G represents phenyl, 2-chlorophenyl,  

 
4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 

4-fluorophenyl, 2-bromophenyl, 2-methylphenyl, 2-methylthiophenyl, 
2-methoxyphenyl, 3-methoxyphenyl, 

4-methoxyphenyl, 4-hydroxyphenyl, 3-trifluoromethylphenyl, 
4-tri-fluoromethoxyphenyl, 2-cyanophenyl, 

2-bromo-4,5- dimethoxyphenyl, 1-naphthyl, 2-naphthyl or 
2,3-dihydrobenzo[b]
furan-7-yl. 
Compounds of formula I as claimed in any preceding 
claim, in which the hydroxy group is in the 7-position. 
Compounds of formula I as claimed in any of claims 1 
to 9, represented by formula III wherein R
7
 represents 
heptanoyl, decanoyl, dodecanoyl, hexadecanoyl or 

octadecanoyl. 
Compounds of formula I as claimed in any of claims 1 
to 9 or 11, represented by formula III wherein the group 

OR
7
 is in the 7-position. 
Compounds of formula I as claimed in claim 1 which 

are: 

1-[1-(2-chlorophenyl)cyclopropyl]-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-hydroxy-6-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-hydroxy-2,6-dimethyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-heptanoyloxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-decanoyloxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline  

 
1-[1-(2-chlorophenyl)cyclopropyl]-7-dodecanoyloxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-hexadecanoyloxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-octadecanoyloxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclopropyl]-7-decanoyloxy-6-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline 
1-[1-(2-chlorophenyl)cyclobutyl]-7-decanoyloxy-6-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline 
 
and pharmaceutically acceptable salts thereof in the 

form of individual enantiomers, racemates or other 
mixtures of enantiomers. 
Pharmaceutical compositions comprising a 
therapeutically effective amount of a compound of 

formula I, together with a pharmaceutically acceptable 
diluent or carrier. 
The use of a compound of formula I as claimed in 
any of claims 1 to 14 as a medicament. 
The use of a compound of formula I as claimed in 
any of claims 1 to 14 as a medicament for analgesia or 

for treating psychoses, Parkinson's disease, Lesch-Nyan 
syndrome, attention deficit disorder or cognitive 

impairment or in the relief of drug dependence or 
tardive dyskinesia. 
The use of a compound of formula I as claimed in 
any of claims 1 to 14 in the manufacture of a medicament 

for analgesia or for treating psychoses, Parkinson's  
 

disease, Lesch-Nyan syndrome, attention deficit disorder 
or cognitive impairment or in the relief of drug 

dependence or tardive dyskinesia. 
A process for the preparation of compounds of 
formula I: 


a) by the cleavage of compounds of formula IV 

 
in which R
3
 is an optionally substituted alkyl group and 
R
4
 is the group R
1
 or is the same as the group OR
3
; or 
b) when R
2
 is methyl, by the methylation of compounds 
of formula V 


 
using formaldehyde and formic acid or formaldehyde and 

sodium cyanoborohydride. 
</CLAIMS>
</TEXT>
</DOC>
